Subscribe to RSS
DOI: 10.4103/0971-3026.169449
Integrated 18F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging (18F-FDG PET/MRI), a multimodality approach for comprehensive evaluation of dementia patients: A pictorial essay
Financial support and sponsorship Nil.Abstract
Dementia, caused by irreversible neurodegenerative disorders such as Alzheimer's disease or reversible non-degenerative conditions, is rapidly becoming one of the most alarming health problems in our aging society. This cognitive disorder associated with a multitude of clinical differentials with overlapping clinical, pathological, and imaging features is difficult to diagnose and treat, as it often presents late after significant neuronal damage has already occurred. Novel disease-modifying treatments being developed will have to be corroborated with innovative imaging biomarkers so that earlier reliable diagnosis can be made and treatment initiated upon. Along with new specific PET radiotracers, integrated PET/MRI with combined methodological advantage and simultaneously acquired structural-cum-functional information may help achieve this goal. The present pictorial essay details our experiences with PET/MRI in dementing disorders, along with reviewing recent advances and future scope.
Keywords
Alzheimer’s disease - amyloid PET - dementia - 18F‑FDG - integrated PET/MRI - vascular dementiaPublication History
Article published online:
30 July 2021
© 2015. Indian Radiological Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
-
References
- 1 Joshi S, Morley JE. Cognitive impairment. Med Clin North Am 2006;90:769-87.
- 2 Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: Final data for 2005. Natl Vital Stat Rep 2008;56:1-120.
- 3 Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, et al.; International Psychogeriatric Association Expert Conference on mild cognitive impairment. Mild cognitive impairment. Lancet 2006;367:1262-70.
- 4 Weytingh MD, Bossuyt PM, van Crevel H. Reversible dementia: More than 10% or less than 1%? A quantitative review. J Neurol 1995;242:466-71.
- 5 Clarfield AM. The decreasing prevalence of reversible dementias: An updated meta-analysis. Arch Intern Med 2003;163:2219-29.
- 6 Hébert R, Brayne C. Epidemiology of vascular dementia. Neuroepidemiology 1995;14:240-57.
- 7 Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143-53.
- 8 Koch T, Iliffe S; EVIDEM-ED project. Rapid appraisal of barriers to the diagnosis and management of patients with dementia in primary care: A systematic review. BMC Fam Pract 2010;11:52.
- 9 Jain P, Wadhwa PK, Jadhav HR. Reactive astrogliosis: Role in Alzheimer's disease. CNS Neurol Disord Drug Targets 2015;14:872-9.
- 10 Pérez DI, Martínez A, Gil C, Campillo NE. From bitopic inhibitors to multitarget drugs for Alzheimer's disease future treatment. Curr Med Chem 2015. [Epub ahead of print].
- 11 Tartaglia MC, Rosen HJ, Miller BL. Neuroimaging in dementia. Neurotherapeutics 2011;8:82-92.
- 12 Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al.; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 2013;12:357-67.
- 13 Vercher-Conejero JL, Rubbert C, Kohan AA, Partovi S, O'Donnell JK. Amyloid PET/MRI in the differential diagnosis of dementia. Clin Nucl Med 2014;39:e336-9.
- 14 Unschuld PG. Possibilities of modern imaging technologies in early diagnosis of Alzheimer disease. Ther Umsch 2015;72:261-9.
- 15 Dukart J, Mueller K, Horstmann A, Barthel H, Möller HE, Villringer A, et al. Combined evaluation of FDG-PET and MRI improves detection and differentiation of dementia. PLoS One 2011;6:e18111.
- 16 Shim H, Ly MJ, Tighe SK. Brain imaging in the differential diagnosis of young-onset dementias. Psychiatr Clin North Am 2015;38:281-94.
- 17 Teipel SJ, Kurth J, Krause B, Grothe MJ; Alzheimer's Disease Neuroimaging Initiative. The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment - Beyond classical regression. Neuroimage Clin 2015;8:583-93.
- 18 Yanase D, Matsunari I, Yajima K, Chen W, Fujikawa A, Nishimura S, et al. Brain FDG PET study of normal aging in Japanese: Effect of atrophy correction. Eur J Nucl Med Mol Imaging 2005;32:794-805.
- 19 Pichler BJ, Judenhofer MS, Catana C, Walton JH, Kneilling M, Nutt RE, et al. Performance test of an LSO-APD detector in a 7-T MRI scanner for simultaneous PET/MRI. J Nucl Med 2006;47:639-47.
- 20 Delso G, Fürst S, Jakoby B, Ladebeck R, Ganter C, Nekolla SG, et al. Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med 2011;52:1914-22.
- 21 Catani C, van der Kouwe A, Benner T, Michel CJ, Hamm M, Fenchel M, et al. Toward Implementing an MRI-based PET attenuation-correction method for neurologic studies on the MR-PET brain prototype. J Nucl Med 2010;51:1431-8.
- 22 Keereman V, Fierens Y, Broux T, De Deene Y, Lonneux M, Vandenberghe S. MRI-based attenuation correction for PET/MRI using ultrashort echo time sequences. J Nucl Med 2010;51:812-8.
- 23 Jena A, Taneja S, Goel R, Renjen P, Negi P. Reliability of semiquantitative 18 F-FDG PET parameters derived from simultaneous brain PET/MRI: A feasibility study. Eur J Radiol 2014;83:1269-74.
- 24 Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-28.
- 25 Scheltens PH. Structural neuroimaging of Alzheimer's disease and other dementias. Aging (Milano) 2001;13:203-9.
- 26 Chen Z, Zhong C. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: Implications for diagnostic and therapeutic strategies. Prog Neurobiol 2013;108:21-43.
- 27 Landau SM, Thomas BA, Thurfjell L, Schmidt M, Margolin R, Mintun M, et al.; Alzheimer's Disease Neuroimaging Initiative. Amyloid PET imaging in Alzheimer's disease: A comparison of three radiotracers. Eur J Nucl Med Mol Imaging 2014;41:1398-407.
- 28 Kawachi T, Ishii K, Sakamoto S, Sasaki M, Mori T, Yamashita F, et al. Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease. Eur J Nucl Med Mol Imaging 2006;33:801-9.
- 29 Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008;131:665-80.
- 30 Karow DS, McEvoy LK, Fennema-Notestine C, Hagler DJ Jr, Jennings RG, Brewer JB, et al.; Alzheimer's Disease Neuroimaging Initiative. Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease. Radiology 2010;256:932-42.
- 31 Zhang D, Shen D; Alzheimer's Disease Neuroimaging Initiative. Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers. PLoS One 2012;7:e33182.
- 32 Jack CR Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, et al.; Alzheimer's Disease Neuroimaging Initiative. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010;133:3336-8.
- 33 Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-9.
- 34 Kanda T, Ishii K, Uemura T, Miyamoto N, Yoshikawa T, Kono AK, et al. Comparison of grey matter and metabolic reductions in frontotemporal dementia using FDG-PET and voxel-based morphometric MR studies. Eur J Nucl Med Mol Imaging 2008;35:2227-34.
- 35 Satishchandra P, Sinha S. Relevance of neuroimaging in the diagnosis and management of tropical neurologic disorders. Neuroimaging Clin N Am 2011;21:737-56, vii.
- 36 Heinemann U, Gawinecka J, Schmidt C, Zerr I. Differential diagnosis of rapid progressive dementia. Eur Neurol Rev 2010;5:21-8.
- 37 Tucker KA, Robertson KR, Lin W, Smith JK, An H, Chen Y, et al. Neuroimaging in human immunodeficiency virus infection. J Neuroimmunol 2004;157:153-62.
- 38 Ragin AB, Storey P, Cohen BA, Epstein LG, Edelman RR. Whole brain diffusion tensor imaging in HIV-associated cognitive impairment. AJNR Am J Neuroradiol 2004;25:195-200.
- 39 Ernst T, Jiang CS, Nakama H, Buchthal S, Chang L. Lower brain glutamate is associated with cognitive deficits in HIV patients: A new mechanism for HIV-associated neurocognitive disorder. J Magn Reson Imaging 2010;32:1045-53.
- 40 Young GS, Geschwind MD, Fischbein NJ, Martindale JL, Henry RG, Liu S, et al. Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: High sensitivity and specificity for diagnosis. AJNR Am J Neuroradiol 2005;26:1551-62.
- 41 Henkel K, Zerr I, Hertel A, Gratz KF, Schröter A, Tschampa HJ, et al. Positron emission tomography with [(18) F] FDG in the diagnosis of Creutzfeldt-Jakob disease (CJD). J Neurol 2002;249:699-705.
- 42 Zhao W, Zhang JT, Xing XW, Huang DH, Tian CL, Jia WQ, et al. Chinese specific characteristics of sporadic Creutzfeldt-Jakob disease: A retrospective analysis of 57 cases. PLoS One 2013;8:e58442.
- 43 Ortega-Cubero S, Pagola I, Luquin MR, Viteri C, Pastor P, Gállego Pérez-Larraya J, et al. Clinical and neuroimaging characteristics of 14 patients with prionopathy: A descriptive study. Neurologia 2015;30:144-52.
- 44 Byrnes KR, Wilson CM, Brabazon F, von Leden R, Jurgens JS, Oakes TR, et al. FDG-PET imaging in mild traumatic brain injury: A critical review. Front Neuroenergetics 2014;5:13.
- 45 Lu L, Wei X, Li M, Li Y, Li W. Emerging MRI and metabolic neuroimaging techniques in mild traumatic brain injury. Neurol India 2014;62:487-91.